GlassScriptPhysician profile
Stephen P Pound
NPI 1962636159
$1,355.61
in general payments reported to CMS, 2019-2025
28 companies · $265 in 2025
The $265 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $101 · 2021: $92.62 · 2022: $116 · 2023: $213 · 2024: $286 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $748 · Education: $16.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $747.51 |
| Education | $16.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $149.64 | 2019-2023 | |
| Biogen, INC. | $143.79 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $139.47 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $138.22 | 2023-2025 | Myfembree |
| Coopersurgical, INC. | $89.64 | 2019-2025 | Paragard T 380a |
| Astellas Pharma US INC | $71.96 | 2019-2025 | Veozah |
| Optumhealth Care Solutions, LLC | $67.13 | 2023 | Vivify Health Care Team Portal, Zyno Solutions |
| Bayer Healthcare Pharmaceuticals INC. | $56.72 | 2020-2025 | |
| Mayne Pharma Commercial LLC | $54.62 | 2021-2025 | |
| Avion Pharmaceuticals | $48.28 | 2019 | |
| Amag Pharmaceuticals, INC. | $42.85 | 2019-2020 | |
| Hologic Sales and Service, LLC | $42.72 | 2020-2022 | |
| Lilly USA, LLC | $40.20 | 2024-2025 | Zepbound |
| Organon LLC | $35.36 | 2024-2025 | Nexplanon |
| Myovant Sciences INC. | $32.70 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $32.69 | 2024 | V-Loc 180, Ligasure |
| Therapeuticsmd, INC. | $29.78 | 2021-2022 | |
| Davol INC. | $22.43 | 2023 | Arista Ah Flexitip |
| Mylan Pharmaceuticals INC. | $18.44 | 2019 | |
| Merck Sharp & Dohme LLC | $17.80 | 2019 | |
| Millicent US INC | $15.57 | 2025 | Femring, Intrarosa |
| Allergan, INC. | $14.54 | 2019 | |
| Daiichi Sankyo INC. | $14.52 | 2024 | Injectafer |
| Exeltis, USA INC. | $13.07 | 2020 | |
| Novo Nordisk INC | $12.06 | 2021 | |
| Amgen INC. | $11.41 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Pound listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.